Participating in a Prostate Cancer Clinical Trial: What Happens Next?

0
(0)

3. Treatment After a Clinical Trial

Depending on the different types of clinical trial, it’s expected that treatment ends with the end of the clinical trial. In some cases, patients continue to receive treatment after the end of the clinical trial, which is known as an “open label extension” of the study. In addition, patients may continue to be followed after receiving treatment in the clinical trial – a period called follow-up.

In the case of study participants of the control groups who were given placebos, they may also receive treatment after the clinical trial. It is important that patients clarify all these conditions and questions with the team responsible for the clinical trial and discuss with them all the options about gaining access to treatment after the end of the clinical trial. Participants should also review any documentation describing the trial, such as the Informed Consent Document.

Find out more about prostate cancer clinical trials here.

Learn more about prostate cancer through this link.

Prostate Cancer News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • NCCN and Rubraca
  • Orgovyx and FDA approval
  • Lynparza
  • Erleada results

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *